SCTX.US Scribe Therapeutics Inc. Common Stock

Healthcare Biotechnology USA Stocks
15.37 USD
Close of Nov 17, 2026
13.50 39.60
Market cap
USD 291M
P/E
-
P/B
-
ROE
-35.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SCTX.US undervalued?

Graham number

The Graham number of Scribe Therapeutics Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Scribe Therapeutics Inc. Common Stock fundamental analysis

No fundamental analysis for Scribe Therapeutics Inc. Common Stock yet.

Scribe Therapeutics Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Scribe Therapeutics Inc. Common Stock

Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution fo…

Full company profile